Following the March 2026 Tavneos vasculitis drug safety alert from the FDA, we are investigating possibly related deaths and liver injuries legal cases to be filed against the drug company Amgen on behalf of patients using Tavneos who developed serious liver side effects or the families of those patients who died. Tavneos Vasculitis Drug … [Read more...]
Ocaliva Label Change Possible After December 2024 FDA Alert
The FDA issued an Ocaliva FDA drug safety alert in December 2024 that may result in another Ocaliva label change. This alert was for cases of liver transplants and liver-related deaths among patients without pre-existing cirrhosis who used Ocaliva as a treatment for primary biliary cholangitis (PBC). To provide context for this most recent … [Read more...]
Menopause Drug Veozah Liver Problems FDA Warnings
A Veozah drug label change made on August 31, 2024, added new warnings about liver toxicity and abnormal liver test results, according to a September 12, 2024, Veozah liver problems FDA Drug Safety Communication. According to the “Additional Information for Patients” section of the September 2024 FDA Veozah liver problems warnings document, … [Read more...]